ValuentumAd

Official PayPal Seal
Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Feb 23, 2017
PBMs: Express Scripts and CVS’ Looming Victory?
Image Source: Victor. We’re expecting a big win at CVS in coming years, and it may come at the expense of Express Scripts.
Feb 18, 2017
Johnson & Johnson's Oncology Division A Force to Be Reckoned With
Image Source: Open Grid Scheduler. Healthcare and consumer staples giant Johnson & Johnson is a core holding in both newsletter portfolios. Let’s take a deep dive into one of its key sources of growth, its ‘Pharmaceutical’ segment.
Feb 15, 2017
These Medical Instruments Won’t Heal Your Portfolio
The medical instruments industry is a group characterized in part by diversity, and as such, there are ideas of all shapes and sizes. Let’s dig into two overvalued companies in the space and what put them in their current positions.
Feb 2, 2017
Exxon Mobil Still Battling Back
Image Source: Exxon Mobil. Exxon Mobil’s reported results are improving as the global oil markets continue to work towards rebalancing. Let’s take a look at the most recent quarter of one of our favorite oil and gas majors.
Feb 1, 2017
Consumer Staples: Product Pricing Gains To Wane in 2017?
Consumer staples giants Kimberly-Clark and Colgate-Palmolive are expecting product pricing growth to be less of a contributor in 2017.
Jan 28, 2017
Nelson’s Earnings Roundup: GOOG(L), PYPL, INTC
Image Source: Aaron Fulkerson. Let’s get President of Valuentum Brian Nelson’s quick thoughts on the earnings reports of Google, PayPal, and Intel, all very important holdings in the newsletter portfolios.
Jan 26, 2017
Alert: Trading MLPs, Adding Boeing, Adding Hanesbrands
Image Source: Ken Teegardin. We’re on the move January 26 in the Dividend Growth Newsletter portfolio.
Jan 24, 2017
Verizon’s Debt Load Is Too Much and Its Deal with Yahoo Is a Silly Distraction
Image Source: Mike Mozart. Verizon’s financial metrics didn’t stack up during 2016, and management suggested 2017 will be more of the same. We’re cautious on this overleveraged, capital-intensive telecom giant.
Jan 24, 2017
J&J Boasts Below-Market Earnings Multiple; Deal with Actelion Not Concerning
Image Shown: J&J’s robust pharma pipeline; source: J&J.There’s a lot to like about J&J’s investment opportunity, not the least of which is its strong pharmaceutical pipeline. Deal-making could challenge its pristine balance sheet, but we don’t expect much to derail our thesis.
Jan 23, 2017
Have Bristol-Myers Squibb’s Shares Finally Found Support?
Image Source: kennijima. Bristol-Myers Squibb has seen its shares fall to $50 from nearly $80 in just the past few months as clinical outcomes of its crucial product Opdivo have come under fire. Have shares finally found support? Let’s have a look.


The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.